Nabla Bio Revolutionizes AI-Driven Protein Design with $26M Series A Funding and Major Pharmaceutical Collaborations

Funding and Collaborations:
Nabla Bio secured $26 million in Series A financing led by Radical Ventures and announced collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda, worth over $550 million in upfront and milestone payments, plus royalties[1][2].

Innovative Platform:
Nabla Bio combines AI and wet-lab technologies to design antibodies against challenging targets such as G protein-coupled receptors (GPCRs), ion channels, and transporters, with a focus on high precision and high-throughput capabilities[1][3].

Therapeutic Potential:
The company's technology aims to unlock previously inaccessible targets, potentially doubling the number of disease-relevant drug targets pursued by the industry[1][4].

Breakthrough in De Novo Antibody Design:
Nabla Bio developed JAM, an AI system that designs de novo antibodies with good affinities, early-stage developability, and function, showing success across a range of soluble and hard-to-drug membrane proteins[5].

Industry Impact:
The collaboration with leading pharmaceutical companies and the development of AI-driven protein design technologies position Nabla Bio at the forefront of a revolution in antibody therapeutics, with profound implications for medicine[1][5].